A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.
Debra Wood
Articles by Debra Wood
Cabozantinib, an oral multikinase inhibitor, showed promise as second- or third-line therapy in patients with advanced differentiated thyroid cancer (DTC).
Latest Updated Articles
Cabozantinib Shows Promise in Second- and Third-line Differentiated Thyroid CancerPublished: October 21st 2015 | Updated:
Immunotherapy May Lead to Abnormal Thyroid Function in Patients With CancerPublished: October 23rd 2015 | Updated: